Evidence mapPaperPMID 40404733Full record

ArticleScientific reports2025

METTL14-mediated miR-122-5p maturation stimulated tumor progression by targeting KAT2A in hepatocellular carcinoma.

Xiangyu Fan, Wenjuan Qiao, Xu Guo, Jiaqi Wang, Lisong Zhao

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiangyu FanDepartment of Radiation Oncology, The Fourth Hospital of Harbin Medical University, No. 37, Yiyuan street, Nangang District, Harbin, 150001, Heilongjiang, China. fxyuwyyx163@163.com.
Wenjuan QiaoDepartment of Radiation Oncology, The Fourth Hospital of Harbin Medical University, No. 37, Yiyuan street, Nangang District, Harbin, 150001, Heilongjiang, China.
Xu GuoDepartment of Radiation Oncology, The Fourth Hospital of Harbin Medical University, No. 37, Yiyuan street, Nangang District, Harbin, 150001, Heilongjiang, China.
Jiaqi WangDepartment of Radiation Oncology, The Fourth Hospital of Harbin Medical University, No. 37, Yiyuan street, Nangang District, Harbin, 150001, Heilongjiang, China.
Lisong ZhaoDepartment of Radiation Oncology, The Fourth Hospital of Harbin Medical University, No. 37, Yiyuan street, Nangang District, Harbin, 150001, Heilongjiang, China.

Funding

Beijing Life Oasis Public Service Center KC2022-JX-0123-01Beijing Science and Technology Innovation Medical Development Foundation cphcf-2022-196
6 · The paper itself

Abstract

m6A modifications are involved in regulating microRNA (miRNA) processing and maturation, and are associated with tumor development. Therefore, this study was aimed to explore the mechanism of miR-122-5p in regulating hepatocellular carcinoma (HCC) progression. mRNA expression and transfection efficiency were detected by RT-qPCR. Western blot was employed to measure protein level. Cell functions were evaluated through CCK-8 and transwell, respectively. Intracellular m6A levels were analyzed by MeRIP. Dual luciferase reporter gene, RIP and co-IP were applied to verify the binding relationship. Xenograft tumor model was carried out for in vivo validation of miR-122-5p function. We reported that miR-122-5p was clearly lessened in HCC. Functionally, miR-122-5p introduction inhibited the malignant progression of HCC. Mechanistically, METTL14 insertion promoted miR-122-5p maturation by labeling pri-miR-122 with m6A. In addition, miR-122-5p exerted suppressor effects by targeting Lysine acetyltransferase 2 A(KAT2A). Moreover, we also found that KAT2A overexpression limited β-catenin expression through succinylation modification. Finally, animal data also illustrated that miR-122-5p introduction could hinder the growth of HCC tumors in vivo. We revealed the existence of a METTL14/miR-122-5p/KAT2A/β-catenin mechanistic axis in HCC, which has not been reported in the literature. This newly discovered mechanistic axis may provide new ideas for HCC therapy.

Indexed as

Carcinoma, HepatocellularHistone AcetyltransferasesLiver NeoplasmsMethyltransferasesMicroRNAsAnimalsbeta CateninCell Line, TumorCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleMiceMice, Nudebeta CateninHistone AcetyltransferasesMethyltransferasesMETTL14 protein, humanMicroRNAsMIRN122 microRNA, humanHCCKAT2Am6AMETTL14miR-122-5p

Identifiers

PMID40404733
PMCPMC12098893

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.